X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs DR. REDDYS LAB - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD DR. REDDYS LAB ORCHID PHARMA LTD/
DR. REDDYS LAB
 
P/E (TTM) x 0.2 40.4 0.4% View Chart
P/BV x 0.2 3.1 6.7% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 ORCHID PHARMA LTD   DR. REDDYS LAB
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
DR. REDDYS LAB
Mar-17
ORCHID PHARMA LTD/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1943,397 5.7%   
Low Rs352,560 1.4%   
Sales per share (Unadj.) Rs276.5856.5 32.3%  
Earnings per share (Unadj.) Rs-79.278.0 -101.6%  
Cash flow per share (Unadj.) Rs-43.5139.9 -31.1%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs53.9739.8 7.3%  
Shares outstanding (eoy) m70.45165.74 42.5%   
Bonus/Rights/Conversions ESOPBB-  
Price / Sales ratio x0.43.5 11.9%   
Avg P/E ratio x-1.438.2 -3.8%  
P/CF ratio (eoy) x-2.621.3 -12.4%  
Price / Book Value ratio x2.14.0 52.7%  
Dividend payout %025.7 0.0%   
Avg Mkt Cap Rs m8,067493,632 1.6%   
No. of employees `0002.822.7 12.3%   
Total wages/salary Rs m2,52731,068 8.1%   
Avg. sales/employee Rs Th6,956.16,259.0 111.1%   
Avg. wages/employee Rs Th902.51,369.8 65.9%   
Avg. net profit/employee Rs Th-1,993.0569.7 -349.8%   
INCOME DATA
Net Sales Rs m19,477141,961 13.7%  
Other income Rs m4071,715 23.7%   
Total revenues Rs m19,884143,676 13.8%   
Gross profit Rs m1,10324,722 4.5%  
Depreciation Rs m2,51910,266 24.5%   
Interest Rs m5,227634 824.4%   
Profit before tax Rs m-6,23615,537 -40.1%   
Minority Interest Rs m200-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1252,965 -4.2%   
Profit after tax Rs m-5,58012,921 -43.2%  
Gross profit margin %5.717.4 32.5%  
Effective tax rate %2.019.1 10.5%   
Net profit margin %-28.79.1 -314.8%  
BALANCE SHEET DATA
Current assets Rs m11,01496,837 11.4%   
Current liabilities Rs m32,06084,199 38.1%   
Net working cap to sales %-108.18.9 -1,213.8%  
Current ratio x0.31.2 29.9%  
Inventory Days Days9573 129.3%  
Debtors Days Days3498 34.4%  
Net fixed assets Rs m29,440102,552 28.7%   
Share capital Rs m705829 85.0%   
"Free" reserves Rs m2,043121,792 1.7%   
Net worth Rs m3,800122,621 3.1%   
Long term debt Rs m9,0185,449 165.5%   
Total assets Rs m46,510218,165 21.3%  
Interest coverage x-0.225.5 -0.8%   
Debt to equity ratio x2.40 5,340.5%  
Sales to assets ratio x0.40.7 64.4%   
Return on assets %-0.86.2 -12.2%  
Return on equity %-146.910.5 -1,393.7%  
Return on capital %-3.712.9 -29.0%  
Exports to sales %37.954.6 69.4%   
Imports to sales %22.69.4 241.9%   
Exports (fob) Rs m7,37877,520 9.5%   
Imports (cif) Rs m4,40613,274 33.2%   
Fx inflow Rs m7,51381,670 9.2%   
Fx outflow Rs m5,64926,355 21.4%   
Net fx Rs m1,86555,315 3.4%   
CASH FLOW
From Operations Rs m1,68221,444 7.8%  
From Investments Rs m-9,860-18,404 53.6%  
From Financial Activity Rs m6,644-3,692 -180.0%  
Net Cashflow Rs m-1,535-1,144 134.2%  

Share Holding

Indian Promoters % 32.3 25.5 126.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 5.4 85.2%  
FIIs % 3.3 35.3 9.3%  
ADR/GDR % 4.6 18.5 24.9%  
Free float % 55.3 15.3 361.4%  
Shareholders   84,811 75,885 111.8%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 219 Points Lower; Energy and Auto Stocks Witness Selling(Closing)

After witnessing volatile trades during the day, Indian share markets ended their session on a negative note. Losses were largely seen in the oil & gas sector, auto sector.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jun 25, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 5-YR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS